Articles tagged with Alzheimer Disease
A study using PET imaging reveals that women with the ApoE 4 allele are more susceptible than men to tau accumulation in the brain. The study also found that sex modulates the effect of ApoE ε4 on brain tau depositing in individuals with mild cognitive impairment.
A study has identified a key connection between two damaging proteins in Alzheimer's disease: amyloid beta and tau. Immune cells called microglia may be the missing link between these proteins, which can cause brain tissue damage.
A new study reveals that close-range blast exposure among Iraq and Afghanistan war vets may lead to degradation of white matter, a key factor in neurodegeneration. Veterans with the APOE ε4 allele, a well-known genetic risk factor for AD, are more susceptible to these effects.
A study of nearly 60,000 individuals suggests that those at higher risk of developing Alzheimer's disease due to family history may demonstrate changes in memory performance as early as their 20s. This risk is particularly pronounced among men and those with lower educational attainment, diabetes, and certain genetic changes.
Researchers from McMaster University mapped a toxic protein linked to Alzheimer's disease, providing new insights into its behavior and interactions with neurons. The findings highlight the importance of understanding the structural features that differentiate toxic and non-toxic forms of amyloid beta.
Researchers have identified the underlying mechanism behind reduced brain blood flow in Alzheimer's disease, which is caused by pericytes contracting around blood vessels. The study suggests that keeping pericytes relaxed could be a key to treating the disease, with new treatments potentially targeting this area.
Researchers found that nilvadipine increased blood flow to the hippocampus, a region affected by Alzheimer's disease, without affecting other parts of the brain. The study suggests that this may slow down the progression of the disease, particularly in its early stages.
Researchers found a link between sleep patterns and Alzheimer's disease pathology, suggesting new diagnostic tools and prevention strategies.
Research found that superoxide dismutase improves cognition by fighting oxidative damage but loses effectiveness when tau proteins increase, suggesting a losing battle against Alzheimer's disease. Increasing SOD1 production may delay progression of the disease, according to Iowa State University researchers.
A longitudinal study found that a food for special medical purposes containing Fortasyn Connect can benefit patients with mild cognitive impairment who are at high risk of progressing to the dementia stage of AD. The product showed significant worsening in memory performance and executive functions in those without intervention, while ...
Researchers at the University of South Florida have identified a potential new therapeutic target for Alzheimer's disease, an antagonist that blocks specific interactions between apoE and amyloid precursor protein. This peptide antagonist, 6KApoEp, was shown to reduce beta amyloid accumulation and tau pathologies in the brain.
Researchers found that smarter, more educated people have a 'cognitive reserve' that helps them perform better at baseline, but this doesn't affect their actual decline rate. Higher education levels are associated with lower rates of Alzheimer's disease in midlife, regardless of age or brain amyloid beta protein levels.
Researchers developed a new computational tool based on Graph theory to infer large-scale regulatory networks from healthy and pathological organs. They were able to pinpoint genes relevant to organ function and potential drivers of diseases, such as type 2 diabetes and Alzheimer's disease.
A new protein, CAPON, has been linked to the connection between amyloid-β plaques and tau pathology in Alzheimer's disease. Accumulation of CAPON increases AD-related pathology, while deficiency reduces symptoms. The study uses novel mouse models to explore this link.
Researchers have discovered a clear connection between gum disease and Alzheimer's disease, finding that the bacteria causing gingivitis can move from the mouth to the brain. Brushing teeth and using floss may help slow down Alzheimer's progression, according to the study.
SORLA promotes HER2 receptor recycling and cancer cell proliferation. Removing SORLA from HER2 positive cancer cells inhibits tumor growth and formation.
Researchers found a link between high LDL cholesterol levels and early-onset Alzheimer's, suggesting LDL may play a causal role in the development of the disease. APOE E4 and other gene variants also explain some cases, but the study suggests cholesterol could be an independent risk factor.
Researchers found that specific financial skills declined with age and at the earliest stages of mild memory impairment. As amyloid plaques buildup increases, a person's ability to understand and apply basic financial concepts declines, making financial management falters more likely.
Researchers found that new neurons continue to form well into old age, including in people with cognitive impairment and Alzheimer's disease. The study provides evidence that neurogenesis may moderate the effects of brain pathology, suggesting potential therapeutic possibilities.
A new study from the University of Cambridge suggests that virtual reality can spot navigation problems in early Alzheimer's disease, a condition affecting over 525,000 people in the UK. The research highlights the potential of new technologies to help diagnose and monitor conditions like Alzheimer's.
Researchers investigating the link between aging fat cells and Alzheimer's disease have found that fat cells play a crucial role in supporting neuronal growth and survival. The study suggests targeting a specific receptor, PPAR-γ2, could lead to a new treatment for Alzheimer's.
Researchers have identified a new mechanism that accelerates aging in the brain and gives rise to the most devastating biological features of Alzheimer's disease. This finding unifies three long-standing theories behind the disease's origins into one cohesive narrative.
A team of researchers has mapped the molecular structure and dynamics of an aggressive protein modification linked to Alzheimer's disease. The study found that this modification accelerates disease progression, causing toxic protein fragments to aggregate into sticky plaques that disrupt brain cell communication.
Researchers found that long-term antibiotic treatment alleviates Alzheimer's disease symptoms in male mice by reducing inflammation and slowing amyloid plaque growth. However, the same treatment had no effect on female animals, with changes in the gut microbiome leading to increased proinflammatory factors.
A study by Lund University researchers shows that blocking the galectin-3 protein reduces Alzheimer's plaque and inflammation in mice. The protein is also involved in Parkinson's disease and stroke inflammation. Inhibiting galectin-3 with inhibitors can reduce its effects, offering potential treatment avenues.
Researchers have identified compounds in ragweed that can help nerve cells survive with Alzheimer's disease peptides. The compounds, including terpenoids and spermidine conjugates, showed promise in protecting neurons from Aβ-induced toxicity.
A University of South Florida study reveals cofilin plays an essential role in worsening tau pathology, leading to brain cell death and neurodegenerative disorders like Alzheimer's. The research proposes inhibiting SSH1 as a potential target for treating Alzheimer's disease.
Scientists at Johns Hopkins Medicine identified average brain changes linked to Alzheimer's disease that occur 3-10 years before symptoms appear. Researchers found subtle cognitive test score changes and protein increases in cerebrospinal fluid an average of 34.4 years before cognitive impairment onset.
PRI-002, a new Alzheimer's drug candidate, has successfully completed Phase I clinical research, demonstrating improved cognitive performance in human trials. The compound destroys toxic oligomers without involving the immune system, offering a promising approach to treating Alzheimer's disease.
A new study found that approximately half of former professional athletes with multiple concussions had higher than normal levels of tau protein in their cerebrospinal fluid, linked to chronic traumatic encephalopathy (CTE). The athletes with high tau levels scored lower on cognitive tests and brain scans showed white matter damage.
Researchers found that visual stimulation can prevent neuron degeneration and enhance synaptic function in Alzheimer's disease models. The treatment also improved spatial memory performance in older mice without a predisposition for the disease.
Researchers are testing a non-invasive procedure that uses low-intensity focused ultrasound to open the blood-brain barrier, allowing treatment to reach the brain and potentially treating neurodegenerative diseases such as Alzheimer's. The clinical trial aims to understand the effectiveness of this method in improving cognitive decline.
Researchers analyzed postmortem brain samples from 24 people with Alzheimer's and 24 without the disease to identify cellular pathways affected by the disease. The study found that axon myelination is disrupted in patients, and gene expression patterns vary significantly between men and women, suggesting potential new drug targets.
Researchers detected and measured specific prion forms of amyloid beta (A-β) and tau proteins in human brain tissue, strongly associated with early-onset Alzheimer's disease. The findings suggest that active A-β and tau prions could drive the disease and prompt exploration of new therapies targeting prions.
A study found that eliminating senescent oligodendrocyte progenitor cells can reduce brain damage and inflammation, slowing cognitive decline in mice with Alzheimer's-like symptoms. The treatment, which combines two FDA-approved drugs, was shown to effectively eliminate these cells and protect against cognitive decline.
A new form of dementia, Limbic-predominant age-related TDP-43 encephalopathy (LATE), has been characterized by researchers. LATE affects multiple areas of cognition and its progression is more gradual than Alzheimer's disease. Further research into LATE may lead to the development of disease-specific drugs.
Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) is a newly-defined brain disorder resembling Alzheimer's disease but caused by misfolded TDP-43 protein. It affects 25% of individuals over 85 years old, causing gradual cognitive decline and impacting daily life.
A newly recognized brain disorder called Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) has been defined with recommended diagnostic criteria. LATE is characterized by cognitive impairment and hippocampal sclerosis, similar to Alzheimer's disease, but progresses more gradually.
Researchers studied how microglia cells in the brain respond to toxic proteins associated with Alzheimer's disease. The study found that age, sex, and genetics affect microglial response, suggesting that modulating this response could lead to new treatments.
Cognitively normal adults with elevated levels of amyloid-β exhibited mixed attitudes toward physician-assisted death, reflecting complex emotions and values surrounding end-of-life care. The study highlights the need for nuanced discussions about dying wishes and advance care planning in this vulnerable population.
Researchers developed a video game to study spatial orientation and navigational abilities, finding that virtual navigation performance is comparable to the real world. The game was played by 4 million people and showed changes in navigational habits before clinical Alzheimer's symptoms appear.
A specially designed mobile game, Sea Hero Quest, can detect people at risk of Alzheimer's by analyzing their spatial navigation skills. Researchers found that those with a high genetic risk, like the APOE4 gene, performed worse on the game, highlighting a potential early detection method.
Researchers discover that disrupting the interaction between amyloid precursor protein and cholesterol leads to neurodegeneration, swelling of synapses, and fragmentation of axons. This finding suggests a new theory on Alzheimer's disease, where amyloid precursor protein may be an accomplice to cholesterol deficiency.
Scientists discovered eight distinct cell populations in zebrafish brains that proliferate in response to amyloid-β aggregates, a hallmark of Alzheimer's disease. These populations may serve as potential targets for inducing regeneration and developing new treatments for humans.
Long-term thiazide use significantly reduces the risk of low-energy fractures in people with Alzheimer's disease. The association was strongest for hip fractures, which saw a 30% decrease in risk.
Researchers analyzed neurofilament light protein in blood samples to detect accelerating nerve cell damage in the brain. The study suggests that blood tests can indicate if a drug affects nerve cell loss, improving diagnosis and treatment of Alzheimer's disease.
Researchers have developed synthetic peptides that target and inhibit small, toxic aggregates of amyloid beta, implicated as the toxic elements behind Alzheimer's disease. The peptides reduce amyloid beta-triggered toxicity in human neural cells and inhibit oligomers in laboratory animal models.
A recent study by Dr. David Munoz reveals the APOE ε4 allele affects sleep patterns differently in women and men with Alzheimer's disease. The research found carriers of this gene variant experience more nighttime disturbances than non-carriers, highlighting a gender-based effect on sleep behavior.
Researchers found a strong correlation between abnormal proteins and criminal behavior in dementia sufferers, especially those with frontotemporal dementia. The study of 220 deceased patients showed that 42% of FTD patients committed repeated crimes, compared to 15% of Alzheimer's patients.
Researchers found elevated tau protein levels in brain regions affected by CTE in living former NFL players with cognitive and mood symptoms. The study also discovered a correlation between years of tackle football played and tau protein levels.
A new survey tool assesses rural, older adults' knowledge of Alzheimer's disease and finds that many are aware of the importance of annual cognitive screenings. However, there are gaps in knowledge about risk factors, symptoms, and treatment options.
Researchers found evidence of gum bacteria in brain samples from people with Alzheimer's disease, suggesting a link between the two conditions. A study using mice showed that the bacterium can migrate from the mouth to the brain, and an experimental drug is currently being tested for its potential to treat Alzheimer's.
Researchers at McGill University tested the effectiveness of naproxen, a common NSAID, in preventing Alzheimer's disease. The two-year trial found no evidence that the medication slowed disease progression or reduced cognitive decline in people with a strong family history of AD.
Researchers detected vascular changes in the human eye using an infrared camera, providing a new potential biomarker for identifying individuals at high risk of progressing to Alzheimer's. The study aims to explore the correlation between retinal capillaries and other brain biomarkers.
A new state-of-the-art sleep unit has opened at the University of East Anglia, pioneering research will investigate the link between sleep and dementia. The unit aims to determine whether treating sleep disturbances early on could help slow down the progression of Alzheimer's disease.
A new study found that increasing levels of protein MFN1 can counterbalance mutated protein MFN2 in Charcot-Marie-Tooth disease and improve mitochondrial function. This approach may also be effective for other neurodegenerative diseases, including Alzheimer's and Parkinson's, which affect millions of people worldwide.
Researchers have discovered a new PET imaging biomarker that can better predict the progression of Alzheimer's disease. Microglial activation levels, as measured by TSPO-PET imaging, showed a significant correlation with cognitive outcomes in an amyloid mouse model.
A new drug targeting brain inflammation, MW-151, is ready for its first round of human testing. The medication aims to block 'bad' inflammation that destroys neurons in Alzheimer's disease.
A nationwide study found that amyloid PET imaging significantly influenced clinical management of patients with mild cognitive impairment and dementia. The technique altered diagnoses and treatment plans in nearly two-thirds of cases, more than double predictions.
Researchers have discovered that two brain regions guide navigation in familiar and new environments. The hippocampus plays a role in tracking distance in new environments, while the retrosplenial cortex takes over when navigating well-known places. This finding helps explain why Alzheimer's patients experience severe disorientation.